Short Interest in Enfusion, Inc. (NYSE:ENFN) Drops By 14.1%

Enfusion, Inc. (NYSE:ENFN) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 14.1% from the September 30th total of 1,770,000 shares. Currently, 3.1% of the shares of the company are short sold. Based on an average trading volume of 376,900 shares, the short-interest ratio is presently 4.0 days.

Hedge Funds Weigh In On Enfusion

Several hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in shares of Enfusion in the 1st quarter valued at $44,000. Wasatch Advisors LP lifted its holdings in shares of Enfusion by 34.2% in the first quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock worth $7,327,000 after acquiring an additional 201,771 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Enfusion in the 1st quarter valued at approximately $452,000. Swiss National Bank grew its holdings in shares of Enfusion by 20.0% during the 1st quarter. Swiss National Bank now owns 69,700 shares of the company’s stock valued at $645,000 after purchasing an additional 11,600 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Enfusion during the 1st quarter worth approximately $122,000. 81.05% of the stock is owned by institutional investors.

Enfusion Trading Up 0.9 %

Shares of NYSE:ENFN traded up $0.08 on Tuesday, reaching $9.24. 10,582 shares of the company’s stock were exchanged, compared to its average volume of 365,205. The company has a fifty day moving average of $8.68 and a 200-day moving average of $8.85. Enfusion has a twelve month low of $7.52 and a twelve month high of $10.45. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of 229.06, a PEG ratio of 2.46 and a beta of 0.92.

Enfusion (NYSE:ENFN) last released its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $49.46 million for the quarter, compared to analyst estimates of $50.27 million. Enfusion had a return on equity of 6.17% and a net margin of 1.98%. As a group, equities research analysts forecast that Enfusion will post 0.07 EPS for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.